{"nctId":"NCT02538666","briefTitle":"An Investigational Immuno-therapy Study of Nivolumab, or Nivolumab in Combination With Ipilimumab, or Placebo in Patients With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based Chemotherapy","startDateStruct":{"date":"2015-10-13","type":"ACTUAL"},"conditions":["Lung Cancer"],"count":907,"armGroups":[{"label":"Nivolumab monotherapy","type":"EXPERIMENTAL","interventionNames":["Biological: Nivolumab"]},{"label":"Nivolumab and ipilimumab combination therapy","type":"EXPERIMENTAL","interventionNames":["Biological: Nivolumab","Biological: Ipilimumab"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Other: Placebo"]}],"interventions":[{"name":"Nivolumab","otherNames":["Opdivo"]},{"name":"Ipilimumab","otherNames":["Yervoy"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects with histologically or cytologically confirmed extensive stage disease SCLC\n* Ongoing response of stable disease or better following 4 cycles of platinum-based first line chemotherapy\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n\nExclusion Criteria:\n\n* Subjects with symptomatic Central Nervous System (CNS) metastases\n* Subjects receiving consolidative chest radiation\n* Subjects with active, known, or suspected autoimmune disease are excluded\n* All side effects attributed to prior anti-cancer therapy must have resolved to Grade 1 or baseline\n\nOther protocol-defined inclusion/exclusion criteria apply","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Overall Survival (OS) of Nivolumab + Ipilimumab Versus Placebo In The Global Population","description":"OS was defined as the time from randomization to the date of death. A participant who had not died was censored at last known alive date. OS was followed up during the blinded study drug treatment and every 3 months via in-person or phone contact after participant discontinued the blinded study drug","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.56","spread":null},{"groupId":"OG001","value":"9.17","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS) of Nivolumab Versus Placebo","description":"Overall Survival (OS) comparing nivolumab monotherapy versus placebo. OS was defined as the time from randomization to the date of death. A participant who had not died was censored at last known alive date. OS was followed up during the blinded study drug treatment and every 3 months via in-person or phone contact after participant discontinued the blinded study drug.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.56","spread":null},{"groupId":"OG001","value":"10.18","spread":null},{"groupId":"OG002","value":"9.28","spread":null},{"groupId":"OG003","value":"8.18","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS) of Nivolumab + Ipilimumab Versus Nivolumab","description":"Overall Survival (OS) comparing Nivolumab + Ipilimumab Versus Nivolumab. OS was defined as the time from randomization to the date of death. A participant who had not died was censored at last known alive date. OS was followed up during the blinded study drug treatment and every 3 months via in-person or phone contact after participant discontinued the blinded study drug.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.18","spread":null},{"groupId":"OG001","value":"9.17","spread":null},{"groupId":"OG002","value":"8.18","spread":null},{"groupId":"OG003","value":"10.48","spread":null}]}]}]},{"type":"SECONDARY","title":"Progression Free Survival (PFS) Per BICR","description":"PFS was defined as the time between the date of randomization and the first date of documented progression as determined by Blind Independent Central Review (BICR) or death due to any cause, whichever occurred first. Participants who died with no reported progression were considered to have progressed on the date of death. Participants who did not progress or die were censored on the date of their last evaluable tumor assessment on or prior to initiation of the subsequent anti-cancer therapy. Participants who did not have any on study tumor assessments and did not die (or died after initiation of the subsequent anti- cancer therapy) were censored on their date of randomization. Participants who started any subsequent anti- cancer therapy without a prior reported Progressive Disease (PD) per BICR were censored at the last evaluable tumor assessment on or prior to initiation of the subsequent anti-cancer therapy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.41","spread":null},{"groupId":"OG001","value":"1.94","spread":null},{"groupId":"OG002","value":"1.74","spread":null},{"groupId":"OG003","value":"1.38","spread":null},{"groupId":"OG004","value":"1.58","spread":null},{"groupId":"OG005","value":"1.54","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS) in Tumor Mutational Burden (TMB) High and Low Subgroups by TMB Cutoff In The Global Population","description":"Tumor mutational burden (TMB) is measured using FoundationOne CDxTM (F1CDx) assay, a comprehensive genomic profile (CGP) assay based on baseline tumor tissue. TMB is defined as the number of somatic, coding, base substitution, and indel mutations per megabase of genome examined.\n\nOS in TMB by the following cutoff points: ≥10 mutations/mb, \\< 10 mutations/mb, ≥13 mutations/mb, \\<13 mutations/mb","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.96","spread":null},{"groupId":"OG001","value":"12.81","spread":null},{"groupId":"OG002","value":"10.55","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.20","spread":null},{"groupId":"OG001","value":"9.76","spread":null},{"groupId":"OG002","value":"8.11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.69","spread":null},{"groupId":"OG001","value":"12.98","spread":null},{"groupId":"OG002","value":"13.47","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.02","spread":null},{"groupId":"OG001","value":"9.89","spread":null},{"groupId":"OG002","value":"7.85","spread":null}]}]}]},{"type":"SECONDARY","title":"Progression Free Survival (PFS) Per BICR in Tumor Mutational Burden (TMB) High and Low Subgroups by TMB Cutoff In The Global Population","description":"Tumor mutational burden (TMB) is measured using FoundationOne CDxTM (F1CDx) assay, a comprehensive genomic profile (CGP) assay based on baseline tumor tissue. TMB is defined as the number of somatic, coding, base substitution, and indel mutations per megabase of genome examined.\n\nPFS in TMB by the following cutoff points: ≥10 mutations/mb, \\< 10 mutations/mb, ≥13 mutations/mb, \\<13 mutations/mb.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.58","spread":null},{"groupId":"OG001","value":"2.79","spread":null},{"groupId":"OG002","value":"2.33","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.41","spread":null},{"groupId":"OG001","value":"1.61","spread":null},{"groupId":"OG002","value":"1.48","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.58","spread":null},{"groupId":"OG001","value":"2.76","spread":null},{"groupId":"OG002","value":"2.63","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.41","spread":null},{"groupId":"OG001","value":"1.84","spread":null},{"groupId":"OG002","value":"1.48","spread":null}]}]}]},{"type":"POST_HOC","title":"Overall Survival (OS) of Nivolumab + Ipilimumab Versus Placebo - Extended Collection","description":"Overall survival (OS) comparing nivolumab + ipilimumab versus placebo. OS was defined as the time from randomization to the date of death. A participant who had not died was censored at last known alive date. OS was followed up during the blinded study drug treatment and every 3 months via in-person or phone contact after participant discontinued the blinded study drug.\n\nNote: This outcome measure represents an updated version of the primary endpoint to include additional data collection that has occurred after the primary completion date. (Assessments were made until 11-Nov-2021).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.56","spread":null},{"groupId":"OG001","value":"9.17","spread":null},{"groupId":"OG002","value":"9.28","spread":null},{"groupId":"OG003","value":"10.48","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":117,"n":273},"commonTop":["Decreased appetite","Fatigue","Nausea","Diarrhoea","Cough"]}}}